.jpg)
1 hour ago
2
Article content
THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLY
Subscribe now to read the latest news in your city and across Canada.
- Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman, and others.
- Daily content from Financial Times, the world's leading global business publication.
- Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.
- National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.
- Daily puzzles, including the New York Times Crossword.
SUBSCRIBE TO UNLOCK MORE ARTICLES
Subscribe now to read the latest news in your city and across Canada.
- Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman and others.
- Daily content from Financial Times, the world's leading global business publication.
- Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.
- National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.
- Daily puzzles, including the New York Times Crossword.
REGISTER / SIGN IN TO UNLOCK MORE ARTICLES
Create an account or sign in to continue with your reading experience.
- Access articles from across Canada with one account.
- Share your thoughts and join the conversation in the comments.
- Enjoy additional articles per month.
- Get email updates from your favourite authors.
THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK.
Create an account or sign in to continue with your reading experience.
- Access articles from across Canada with one account
- Share your thoughts and join the conversation in the comments
- Enjoy additional articles per month
- Get email updates from your favourite authors
Sign In or Create an Account
or
Article content
BALTIMORE — Protaryx Medical, an innovative medical device company developing disruptive access solutions for minimally invasive left-heart procedures, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market the proprietary Transseptal Puncture Device.
Article content
Article content
This milestone represents a significant advancement in the Company’s mission to redefine safe, efficient, and reproducible left heart access for cardiac interventions, enabling broader adoption and improved delivery of minimally invasive therapies.
Article content
Article content
Key Highlights
Article content
By signing up you consent to receive the above newsletter from Postmedia Network Inc.
Article content
- The system is designed to support zero-exchange delivery and features a unique atraumatic design that reduces procedural steps and the need for rewiring, resulting in improved workflow efficiency.
- The device incorporates a highly echogenic, extendable atraumatic positioning probe and a standardized RF guidewire compatible with commercially available electrosurgical generators.
- Enables precise, site-specific transseptal puncture (TSP) to optimize access and positioning for cardiac interventions, reducing the risk of suboptimal device alignment, procedural complexity, and downstream clinical complications.
- In an early First-in-Human study (n=5), the device demonstrated procedural success in all cases with no reported device-related adverse events, minimal crossing time, and reduced fluoroscopic exposure.
Article content
Company Commentary
Article content
“Receiving FDA 510(k) clearance is a defining moment for Protaryx,” said David Mester, Chief Executive Officer of Protaryx Medical. “This achievement reflects the dedication of our team to solving one of the most critical challenges in safe and efficient transseptal access procedures. We are now positioned to bring this transformative technology to physicians and patients across the United States.”
Article content
Protaryx co-founder and System Chief of Cardiac Surgery at Johns Hopkins medicine, Dr. James Gammie, added: “This clearance underscores the strength of the technology and its potential to set a new standard for transseptal puncture. By simplifying access to the left atrium, the device can expand procedural adoption while improving safety, precision, and ease-of-use.”
Article content
Interventional cardiologist Dr. Gagan Singh (UC Davis Health), who participated in the FIH study, previously noted the device’s “superior echogenicity, atraumatic design, and ease of use,” highlighting its ability to reduce the learning curve and enable more targeted, efficient procedures.
Article content
Technology Overview
Article content
The Protaryx Transseptal Puncture Device is a next-generation solution designed to streamline access to the left side of the heart. The system enables zero-exchange catheter procedures and integrates proprietary RF guidewire technology with standard electrosurgical generators. Its highly echogenic, extendable atraumatic probe enhances visualization and positioning, delivering improved workflow efficiency, precision, and safety for operators of all experience levels.
Article content
Article content
With FDA clearance secured, Protaryx Medical plans to initiate U.S. commercialization and expand clinical adoption, supporting physicians in delivering advanced cardiac therapies.
Article content
About Protaryx Medical
Article content
Protaryx Medical is a Baltimore-based medical device company dedicated to enhancing access and procedural efficiency cardiac interventions. The Company’s innovative Transseptal Puncture Device delivers groundbreaking advancements in left-atrial access, simplifying procedures while optimizing workflow and patient outcomes.
Article content
For more information, please visit www.Protaryx.com.
Article content
Forward-Looking Statements
Article content
This press release contains forward-looking statements that involve risks and uncertainties, including statements regarding commercialization plans and market adoption. Actual results may differ materially from those projected. The Company undertakes no obligation to update forward-looking statements.
Article content
Article content
Article content
Article content
View source version on businesswire.com:
Article content
Article content
Article content
Contacts
Article content
Media Contact
Article content
Article content
Protaryx Medical
Article content
Article content
Article content
Article content
667.401.6772
Article content
English (US)